<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="654">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01746706</url>
  </required_header>
  <id_info>
    <org_study_id>2011 A00383-38</org_study_id>
    <nct_id>NCT01746706</nct_id>
  </id_info>
  <brief_title>Can the Assessment of the Subhippocampal Region Contribute to the Detection of Early Diagnosis of Alzheimer's Disease? A Validation Study Using PET With Florbetapir (AV-45).</brief_title>
  <official_title>Can the Assessment of the Subhippocampal Region Contribute to the Detection of Early Diagnosis of Alzheimer's Disease?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reliable diagnosis of Alzheimer's Disease (AD) at the predementia stage is currently&#xD;
      considered to be a priority for research, as disease modifying therapies are being evaluated.&#xD;
      Many studies focus on the functional and morphological assessment of the hippocampal&#xD;
      formation. However, neurofibrillary tangles, associated with cognitive deficits, initially&#xD;
      affect the anterior subhippocampal cortex (transentorhinal, entorhinal and perirhinal cortex)&#xD;
      before reaching the hippocampus. Studies from our group have tried to investigate if the&#xD;
      assessment of subhippocampal regions using cognitive tools and neuroimaging techniques could&#xD;
      contribute to the diagnosis of AD at a very early stage.&#xD;
&#xD;
      In a previous project, the investigators included 40 patients with single domain amnestic MCI&#xD;
      (Mild Cognitive Impairment), known to be at high risk for AD and demonstrated that aMCI&#xD;
      patients with a profile of subhippocampal dysfunction (impaired performance on a visual&#xD;
      recognition memory task) display other clinical as well as imaging profiles of patients with&#xD;
      early AD using MRI and SPECT. Longitudinal follow-up data in these patients is currently&#xD;
      under way. Preliminary data indicates that evaluating the subhippocampal region using visual&#xD;
      recognition tasks is highly predictive of AD over 6 years.&#xD;
&#xD;
      The aim of this project is to obtain additional diagnostic data using a PET amyloid tracer&#xD;
      (Florbetapir F18 AV45 F18), an in-vivo marker of one of the neuropathological lesions that&#xD;
      define AD, of in order to enhance diagnostic accuracy AD in these patients. This approach&#xD;
      will validate the hypothesis as to whether the assessment of subhippocampal dysfunction can&#xD;
      contribute to the early diagnosis of AD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the assessment of subhippocampal dysfunction</measure>
    <time_frame>24month</time_frame>
    <description>PET amyloid tracer (Florbetapir F18 AV45 F18)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET amyloid tracer (Florbetapir F18 AV45 F18</intervention_name>
    <arm_group_label>patients</arm_group_label>
    <arm_group_label>volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        patients:&#xD;
&#xD;
          -  - A score in the MMS (Folstein and al ., on 1975, French version subjected to&#xD;
             consensus of Greco). 24 for the level subjects I (less than 5 years of study), 26 and&#xD;
             more for the others, the autonomy in the everyday life,&#xD;
&#xD;
          -  A lower normal IADL &lt; = 1/4 (Lawton and Brody, on 1969, version 4 items),&#xD;
&#xD;
          -  A complaint mnemonic of the patient&#xD;
&#xD;
          -  A lower performance of 1,5 standard deviation in the standard in the&#xD;
             reminder(abseiling) postponed from the sub-test of logical memory(report) of the&#xD;
             WMS-III and/or in the free reminder(abseiling) postponed from the test(event) of the&#xD;
             California Verbal Learning Test.&#xD;
&#xD;
        volunteers:&#xD;
&#xD;
          -  50-80-year-old and presented an educational level sailed in that of the patients,&#xD;
&#xD;
          -  a MMS upper to 24 for the level subjects I (5 years of study), 26 and more for the&#xD;
             levels 2 and 3,&#xD;
&#xD;
          -  an Autonomy of the everyday life,&#xD;
&#xD;
          -  normal IADL = 0/4&#xD;
&#xD;
          -  did not present mnemonic complaint,&#xD;
&#xD;
          -  a performance normal for the reminder postponed from the subtest of logical memory of&#xD;
             the WMS-III and for the free reminder(abseiling) postponed from the test(event) of the&#xD;
             California Verbal Learning Test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Incapacitated to realize the examination by FART because of medical intercurrent&#xD;
             affections. There are this day no contraindications in the product Florbetapir used&#xD;
             for the TEPscan.&#xD;
&#xD;
          -  The persons under protection of justice cannot be included, because the law forbids&#xD;
             their participation biomedical researches.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BERNARD BELAIGUES</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>mira DIDIC</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP HM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>December 7, 2012</study_first_submitted>
  <study_first_submitted_qc>December 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2012</study_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

